HPV+ oropharyngeal squamous cell carcinomas from patients with two tumors display synchrony of viral genomes yet discordant mutational profiles and signatures.


Journal

Carcinogenesis
ISSN: 1460-2180
Titre abrégé: Carcinogenesis
Pays: England
ID NLM: 8008055

Informations de publication

Date de publication:
11 02 2021
Historique:
received: 25 08 2020
revised: 09 10 2020
accepted: 15 10 2020
pubmed: 20 10 2020
medline: 29 6 2021
entrez: 19 10 2020
Statut: ppublish

Résumé

Human papillomavirus (HPV) positive oropharyngeal squamous cell carcinoma (HPV + OPSCC) is increasing in prevalence in the USA, as are cases of patients with multiple HPV + OPSCCs (mHPV + OPSCC). mHPV + OPSCCs present a unique opportunity to examine HPV + OPSCC mutation acquisition and evolution. We performed sequencing of the viral genome, somatic exome and somatic transcriptome from 8 patients each with 2 spatially distinct HPV + OPSCCs, and 37 'traditional' HPV + OPSCCs to first address if paired tumors are caused by the same viral isolate and next, if acquired alterations, and the underlying processes driving mutagenesis, are shared within pairs. All tumor pairs contained viral genomes from the same HPV type 16 sublineage and differed by 0-2 clonal single nucleotide polymorphisms (SNPs), suggesting infection with the same viral isolate. Despite this, there was significant discordance in expression profiles, mutational burden and mutational profiles between tumors in a pair, with only two pairs sharing any overlapping mutations (3/3343 variants). Within tumor pairs there was a striking discrepancy of mutational signatures, exemplified by no paired tumors sharing high APOBEC mutational burden. Here, leveraging mHPV + OPSCCs as a model system to study mutation acquisition in virally mediated tumors, in which the germline, environmental exposures, immune surveillance and tissue/organ type were internally controlled, we demonstrate that despite infection by the same viral isolate, paired mHPV + OPSCCs develop drastically different somatic alterations and even more strikingly, appear to be driven by disparate underlying mutational processes. Thus, despite a common starting point, HPV + OPSCCs evolve through variable mutational processes with resultant stochastic mutational profiles.

Identifiants

pubmed: 33075810
pii: 5930843
doi: 10.1093/carcin/bgaa111
pmc: PMC8014522
doi:

Substances chimiques

Biomarkers, Tumor 0
DNA, Viral 0

Types de publication

Comparative Study Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

14-20

Subventions

Organisme : NCI NIH HHS
ID : K07 CA218247
Pays : United States
Organisme : NCI NIH HHS
ID : K12 CA090625
Pays : United States

Informations de copyright

© The Author(s) 2020. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Références

Ann Surg Oncol. 2018 Aug;25(8):2323-2331
pubmed: 29770915
Nat Genet. 2013 Sep;45(9):970-6
pubmed: 23852170
Cell. 2017 Sep 7;170(6):1164-1174.e6
pubmed: 28886384
Cancer. 2019 Mar 1;125(5):761-769
pubmed: 30521092
Nat Commun. 2016 Oct 21;7:13200
pubmed: 27767028
Genome Res. 2019 Jan;29(1):1-17
pubmed: 30563911
Oncotarget. 2016 Feb 2;7(5):6201-20
pubmed: 26701847
Papillomavirus Res. 2015 Dec 1;1:3-11
pubmed: 26645052
Nature. 2013 Aug 22;500(7463):415-21
pubmed: 23945592
Virology. 2013 Oct;445(1-2):232-43
pubmed: 23998342
Oral Oncol. 2020 Jan;100:104475
pubmed: 31765835
Proc Natl Acad Sci U S A. 2017 Dec 19;114(51):13573-13578
pubmed: 29208707
Oral Oncol. 2019 Sep;96:140-147
pubmed: 31422205
J Clin Invest. 2017 Aug 1;127(8):2930-2940
pubmed: 28650338
Int J Cancer. 2018 Mar 1;142(5):927-939
pubmed: 29105743
Cancer Discov. 2015 Jul;5(7):704-12
pubmed: 26091828
Oral Oncol. 2017 Nov;74:8-14
pubmed: 29103756
Carcinogenesis. 2018 May 3;39(5):708-718
pubmed: 29546405
Nat Commun. 2016 Jul 05;7:12072
pubmed: 27377421
J Natl Cancer Inst. 2016 Apr 29;108(9):
pubmed: 27130930
Genome Biol. 2014 Aug 27;15(8):433
pubmed: 25159823
Trends Mol Med. 2015 May;21(5):274-84
pubmed: 25820175
Papillomavirus Res. 2019 Jun;7:67-74
pubmed: 30738204

Auteurs

Daniel L Faden (DL)

Department of Otolaryngology-Head and Neck Surgery, Massachusetts Eye and Ear, Boston, MA, USA.
Massachusetts General Hospital, Boston, MA, USA.
Harvard Medical School, Boston, MA, USA.
Broad Institute of MIT and Harvard, Cambridge, MA, USA.

Adam Langenbucher (A)

Massachusetts General Hospital, Boston, MA, USA.

Krystle Kuhs (K)

Department of Medicine, Division of Epidemiology, Vanderbilt University Medical Center, Nashville, TN, USA.

James S Lewis (JS)

Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, TN, USA.
Department of Otolaryngology-Head and Neck Surgery, Vanderbilt University Medical Center, Nashville, TN, USA.

Lisa Mirabello (L)

Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD, USA.

Meredith Yeager (M)

Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD, USA.
Cancer Genomics Research Laboratory, Leidos Biomedical Research, Inc., Frederick, MD, USA.

Joseph F Boland (JF)

Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD, USA.
Cancer Genomics Research Laboratory, Leidos Biomedical Research, Inc., Frederick, MD, USA.

Sara Bass (S)

Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD, USA.
Cancer Genomics Research Laboratory, Leidos Biomedical Research, Inc., Frederick, MD, USA.

Mia Steinberg (M)

Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD, USA.
Cancer Genomics Research Laboratory, Leidos Biomedical Research, Inc., Frederick, MD, USA.

Michael Cullen (M)

Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD, USA.
Cancer Genomics Research Laboratory, Leidos Biomedical Research, Inc., Frederick, MD, USA.

Michael S Lawrence (MS)

Massachusetts General Hospital, Boston, MA, USA.
Harvard Medical School, Boston, MA, USA.
Broad Institute of MIT and Harvard, Cambridge, MA, USA.

Robert L Ferris (RL)

Department of Otolaryngology, University of Pittsburgh, Pittsburgh, PA, USA.
Department of Immunology, University of Pittsburgh, Pittsburgh, PA, USA.
UPMC Hillman Cancer Center, Pittsburgh, PA, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH